Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: BHP Falls After Earnings Miss Expectations

Tue, 20th Aug 2019 10:28

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------J Sainsbury, up 2.5%, Ocado Group, up 2.4%. The UK grocery market was flat in the past three months due to "tough" comparatives with last year's hot summer, a survey by Kantar Worldpanel showed. In the 12 weeks to August 11, supermarket sales were flat compared to a year before, Kantar said. Ocado claimed the top spot as the UK's fastest growing grocer, increasing sales by 13% during the period. The online grocer increased its shopper base by 7% and encouraged its customers to spend GBP1.93 more each delivery, Kantar noted. Sainsbury's accounted for 15.4% of all UK supermarket sales during the 12-week period. Overall Sainsbury's sales fell by 0.6%, however, despite sales of branded goods rising by 1.5%, driven by higher levels of promotion and Sainsbury's price lockdown strategy.----------Antofagasta, up 1.9%. Goldman Sachs raised the copper miner to Neutral from Sell. ----------AstraZeneca, up 1.7%. The Anglo-Swedish drugmaker reported positive results from the third phase of the DAPA-HF trial. Astra said the study showed Farxiga met the primary composite endpoint with a reduction of cardiovascular death or the worsening of heart failure, compared to a placebo.----------FTSE 100 - LOSERS----------Rentokil Initial, down 2.0%. RBC Capital cut the pest control company to Sector Perform from Outperform. ----------BHP Group, down 1.0%. The Anglo-Australian miner reported an improvement in performance in its most recently ended financial year, but results were mostly below what the market had expected. For the 12 months to June, the mining giant's pretax profit rose 2.0% to USD15.05 billion the prior year, while underlying earnings before interest, tax, depreciation, and amortisation were broadly flat year-on-year at USD23.16 billion compared to USD23.18 billion. The underlying Ebitda figure fell short of the USD23.71 billion expected by analysts. BHP's annual revenue from continuing operations was USD44.29 billion, up 2.7% from a year earlier, but again below consensus of USD44.74 billion. "The current negative backdrop would suggest BHP may find it hard to keep growing earnings at the current rate, particularly in the short term," noted AJ Bell's Russ Mould. ----------FTSE 250 - WINNERS----------Mitchells & Butlers, up 3.2%. Canaccord upgraded the pub and restaurant operator to Buy from Hold. ----------IMI, up 1.7%. The engineer IMI announced the USD85 million acquisition of Pennsylvania-based valve and flow control product maker PBM. PBM will join IMI's Critical Engineering division, and IMI said the deal is an "important opportunity" to broaden into an "attractive, adjacent market". PBM registered USD6.8 million of adjusted earnings before interest, tax, depreciation, and amortisation in 2018, on revenue of USD35.6 million. By comparison, FTSE 250-listed IMI delivered revenue of GBP1.91 billion.----------FTSE 250 - LOSERS----------Ashmore Group, down 2.8%. Exane BNP cut the emerging markets-focused asset manager to Neutral from Outperform. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Avesoro Resources, up 27% at 87.70p. Shares in the miner climbed after it said its major shareholder is considering a buyout. The firm is also considering a review of the Youga gold mine, and has suspended guidance due to ongoing problems both at Youga and the New Liberty mine. Avesoro Jersey currently owns 73% of Avesoro, and the company has now said a "non-binding expression of interest" has been made to buy the rest of Avesoro's shares at 100 pence each. The company said shareholders owning 13% of Avesoro have already supported the move. Avesoro Jersey is led by Avesoro Non-Executive Chair Murathan Gunal, a Turkish businessman. On the operational front, Avesoro is now assessing the long-term viability of Burkina Faso's Youga gold mine. Last Wednesday night, a security guard at the mine shot dead a clandestine miner at Youga, which led to a break-in by an armed group of fellow artisanal miners. ----------OTHER MAIN MARKET AND AIM - LOSERS----------Mysale Group, down 47% at 2.5p. The online retailer said it intends to raise at least GBP10.0 million before expenses from a share placing. The online retailer said the placing will enable it to repay its bank debt, meaning that it will operate on a debt-free basis, improving cash flow. The fundraising also will support the restructuring of MySale into an Australia and New Zealand-focused retail marketplace platform - what it calls its "ANZ First" strategy. Some 79% of MySale shareholders have supported the placing of 500.0 million shares at a price of 2.0 pence each. The placing price represents a discount of 58% to the closing price of 4.75 pence on Monday. Looking forward, MySale proposed an open offer for up to a further GBP2.0 million to be launched in due course.----------

More News
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more
6 Sep 2023 07:45

AstraZeneca working with FDA on finer details of Ultomiris treatment

(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).

Read more
4 Sep 2023 15:46

UK dividends calendar - next 7 days

Tuesday 5 September 
no events scheduled 
Wednesday 6 September 
no events scheduled 
Thursday 7 September 
Admiral Group PLCex-dividend payment date
Alpha Financial Markets Consulting PLCex-dividend payment date
Anglo-Eastern Plantations PLCex-dividend payment date
Assura PLCex-dividend payment date
Athelney Trust PLCex-dividend payment date
Baltic Classifieds Group PLCex-dividend payment date
Blackrock World Mining Trust PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
CT UK Capital & Income Investment Trust PLCex-dividend payment date
Derwent London PLCex-dividend payment date
Develop North PLCex-dividend payment date
DS Smith PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Greggs PLCex-dividend payment date
Harbour Energy PLCex-dividend payment date
Pollen Street PLCex-dividend payment date
Prudential PLCex-dividend payment date
Relx PLCdividend payment date
RM Infrastructure Income PLCex-dividend payment date
Serco Group PLCex-dividend payment date
Severfield PLCex-dividend payment date
VPC Specialty Lending Investments PLCex-dividend payment date
XP Power Ltdex-dividend payment date
Zotefoams PLCex-dividend payment date
Friday 8 September 
abrdn New Dawn Investment Trust PLCdividend payment date
Avon Protection PLCdividend payment date
Berkeley Group Holdings PLCdividend payment date
Chemring Group PLCdividend payment date
Ecofin US Renewables Infrastructure Trust PLCdividend payment date
iomart Group PLCdividend payment date
Keller Group PLCdividend payment date
Lookers PLCdividend payment date
Moneysupermarket.com Group PLCdividend payment date
Nichols PLCdividend payment date
Tritax EuroBox PLCdividend payment date
Tyman PLCdividend payment date
Monday 11 September 
AstraZeneca PLCdividend payment date
Games Workshop Group PLCdividend payment date
Rentokil Initial PLCdividend payment date
Residential Secure Income PLCdividend payment date
ThomasLloyd Energy Impact Trust PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
4 Sep 2023 12:13

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

Read more
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more
29 Aug 2023 12:33

US government names first 10 drugs for Medicare price negotiation

Aug 29 (Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program.

Read more
29 Aug 2023 11:00

US to name first 10 drugs for Medicare price negotiation

Aug 29(Reuters) - The Biden administration on Tuesday is expected to release its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people.

Read more
25 Aug 2023 11:59

Novo says Wegovy drug helps obese people with heart failure in trial

Aug 25 (Reuters) - Novo Nordisk said its hugely popular drug Wegovy was shown to substantially ease heart failure in obese people, as the Danish drugmaker seeks to further build its case for the medicine's health benefits beyond weight loss.

Read more
24 Aug 2023 16:24

UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Thursday jointly said its Lynparza treatments have been approved in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.